16:06 EST Compass Therapeutics (CMPX) files $400M mixed securities shelf
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMPX:
- Promising Clinical Data and Market Positioning Drive Buy Rating for Compass Therapeutics
- Canaccord starts Compass Therapeutics with a Buy ahead of tovecimig readout
- Compass Therapeutics initiated with an Overweight at Cantor Fitzgerald
- Compass Therapeutics initiated with a Buy at Canaccord
- Compass Therapeutics initiated with an Outperform at Citizens JMP